Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Gilead Sciences
- Study ID
- NCT02864381
- Phase
- PHASE2
- Status
- Completed
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Andecaliximab — DRUG800 mg administered via IV infusion
- Nivolumab — DRUG3 mg/kg administered via IV infusion
Study Details
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Key Dates
- Start date
- Sep 1, 2016
- Status verified
- Sep 2020
- Primary completion
- Nov 8, 2017
- Completion
- Aug 23, 2019
Study Design
- Enrollment
- 144 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Andecaliximab + NivolumabAndecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
- Active Comparator: NivolumabNivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Up to 41 weeks ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Los Angeles | California | 90095 | - |
| - | San Francisco | California | 94158 | - |
| - | Chicago | Illinois | 60637 | - |
| - | Fort Wayne | Indiana | 46845 | - |
| - | St Louis | Missouri | 63110 | - |
| - | New York | New York | 10065 | - |
Related Studies
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel ChemotherapiesPHASE1 · Recruiting · University of Chicago · Chicago, Illinois
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska
- A Multicenter Cancer Biospecimen Collection StudyRecruiting · Cofactor Genomics, Inc. · San Francisco, California